Ertugliflozin; Sitagliptin Phosphate

For type 2 diabetes mellitus. Sold as Steglujan. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 1 application for Ertugliflozin; Sitagliptin Phosphate (sold as Steglujan), first approved Dec 19, 2017, with 1 new use approved and 0 published complete response letters.

First approved: Dec 19, 2017
Applications: 1
New uses approved: 1
Complete response letters: 0
First approved in the EU: Mar 23, 2018

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

STEGLUJAN 15-100 MG TABLET: $17.59 per unitBrand · -1% in a year

Approvals in the EU (EMA)

First approved in the EU 3 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals

Steglujan, new substanceMerck Sharp & Dohme B.V. · Mar 23, 2018

Clinical Trials

2 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)Cardiovascular Kidney Metabolic Syndrome · Ohio State University	—	Active, not recruiting	Sep 23, 2025
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyCardiovascular Events, Type2 Diabetes · Brigham and Women's Hospital	—	Active, not recruiting	Feb 2, 2022

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Dec 19, 2017	SteglujanNDA 209805 · New combination	Msd Sub Merck	11	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA